Oculis Holding AG (OCS) EBT (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly EBT of -$37.0 million for Q1 2026, little changed year-over-year from -$37.0 million in Q1 2025, and down 24.7% quarter-over-quarter from -$29.6 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) EBT (2022 - 2026) Analysis & Trends
Oculis Holding AG's EBT history runs 5 years deep, the most recent figure standing at -$37.0 million for Q1 2026.
- In Q1 2026, EBT changed 0.1% year-over-year to -$37.0 million; the TTM figure through Mar 2026 stood at -$21.2 billion (up 9.51% YoY), while the FY2025 annual figure was -$119.6 million, down 22.41% from the prior year.
- EBT for Q1 2026 stood at -$37.0 million, down from -$29.6 million in the prior quarter.
- The five-year high for EBT was -$9.5 million in Q4 2022, with the low at -$23.3 billion in Q3 2024.
- The 5-year median for EBT is -$26.3 million (2025), against an average of -$2.8 billion.
- Peak annual rise in EBT reached 62.91% in 2024, while the deepest fall reached 117219.62% in 2024.
- Oculis Holding AG's EBT stood at -$9.5 million in 2022, then plunged by 47.75% to -$14.1 million in 2023, then tumbled by 133.82% to -$33.0 million in 2024, then increased by 10.11% to -$29.6 million in 2025, then dropped by 24.7% to -$37.0 million in 2026.
- Business Quant data shows OCS's EBT at -$37.0 million in Q1 2026, -$29.6 million in Q4 2025, and -$21.1 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Oculis Holding AG | 634.23 Mn | 345.35 Mn | - | -12.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12.61 Mn |
| Mar 31, 2026 | -36.97 Mn |
| Dec 31, 2025 | -29.65 Mn |
| Sep 30, 2025 | -21.05 Mn |
| Jun 30, 2025 | -30.68 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -32.98 Mn |
| Sep 30, 2024 | -23.28 Mn |
| Jun 30, 2024 | -23.01 Mn |
| Mar 31, 2024 | -18.40 Mn |
| Dec 31, 2023 | -14.11 Mn |
| Sep 30, 2023 | -19.85 Mn |
| Jun 30, 2023 | -14.19 Mn |
| Mar 31, 2023 | -49.62 Mn |
| Dec 31, 2022 | -9.55 Mn |
| Sep 30, 2022 | -10.30 Mn |
| Jun 30, 2022 | -12.77 Mn |